CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胶质母细胞瘤患者接受树突状细胞疫苗免疫治疗后，额外进行 O-(2-[18F]氟乙基)-L-酪氨酸 ((18)F-FET) PET 的诊断影响
英文原题：Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine ((18)F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients.
查看英文原题
Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine ((18)F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
尽管患者数量较少，我们的结果表明 18F-FET PET 在监测疫苗接种治疗后的疗效方面具有额外的影响。
研究思路结论见上方概要
目的
使用负载肿瘤抗原的自体树突状细胞（DC）进行疫苗接种治疗，是胶质母细胞瘤（GBM）标准治疗之外一种有前景的治疗方法。然而，关于治疗监测的可靠诊断标准尚未建立。在此，我们分析了DC疫苗接种治疗后额外进行18F-氟乙基酪氨酸正电子发射断层扫描（18F-FET PET）成像的影响。
方法
我们分析了接受DC疫苗接种治疗的GBM患者数据。在MRI诊断肿瘤复发后，进行了额外的静态和动态18 F-FET PET成像。疫苗接种通过皮内注射进行五次，或在同步放化疗和间歇化疗之间每周进行，或在肿瘤复发后、再放疗前进行。将MRI和18 F-FET PET结果进行比较，并与临床数据相关联。
结果
2003年至2016年间，共识别出5名接受DC疫苗接种和18F-FET PET显像的患者（1名女性/4名男性；平均年龄：44 ± 14岁）。5名患者中有3名显示肿瘤进展的结果一致。在3名患者中，18F-FET PET提示治疗相关改变，这与提示肿瘤进展的MRI发现相反。在这些患者中，18F-FET PET结果可通过神经病理学诊断或根据RANO标准得到证实。
展开英文摘要原文
OBJECTIVE
Vaccination therapy using tumour antigen-loaded, autologous dendritic cells (DC) is a promising therapeutic approach alongside standard treatment for glioblastoma (GBM). However, reliable diagnostic criteria regarding therapy monitoring are not established. Here, we analysed the impact of additional 18 F-fluoroethyl-tyrosine positron emission tomography ( 18 F-FET PET) imaging following DC vaccination therapy.
METHODS
We analysed data of GBM patients who received DC vaccination therapy. Following MRI diagnosis of tumour recurrence, additional static and dynamic 18 F-FET PET imaging was performed. Vaccination was performed five times by intradermal injections, either weekly between concomitant radio/-chemotherapy and intermittent chemotherapy or after tumour recurrence, before re-radiation therapy. MRI and 18 F-FET PET results were compared and correlated with clinical data.
RESULTS
Between 2003 and 2016, 5 patients were identified who received DC vaccination and 18 F-FET PET imaging (1 female/4 males; mean age: 44 ± 14 y). 3/5 patients showed congruent results of tumour progression. In three patients 18 F-FET PET indicated treatment related changes, which was in contrast to MRI findings that indicated tumour progression. In these patients 18 F-FET PET results could be confirmed by either neuropathological diagnosis or according to the RANO criteria.
CONCLUSIONS
Despite the small patients number our results indicate an additional impact of 18 F-FET PET for monitoring outcome following vaccination therapy.
论文信息
- 作者
- Kristin Schmitz A、Sorg RV、Stoffels G、Grauer OM、Galldiks N、Steiger HJ、Kamp MA、Langen KJ
- 单位
- Department of Neurosurgery, Faculty of Medicine, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.Germany
- 期刊
- British journal of neurosurgery2021 Dec
- 原文标识
- PubMed 31407920 · DOI 10.1080/02688697.2019.1639615